The role of vasopressin in vasodilatory septic shock

Pharmacotherapy

Volumn 24, Issue 8, 2004, Pages 1050-1063

  Obritsch, Marilee D ^a   Bestul, Daniel J ^a   Jung, Rose ^b   Fish, Douglas N ^b   MacLaren, Robert ^b  

^a UNIVERSITY OF COLORADO HOSPITAL   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Critical care; Septic shock; Vasopressin

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; DOPAMINE; NORADRENALIN; PHENYLEPHRINE; VASOPRESSIN;

ADD ON THERAPY; ARTERIAL PRESSURE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFECT; DRUG EFFICACY; GASTROINTESTINAL MUCOSA; GLOMERULUS FILTRATION; HEART INDEX; HEART MUSCLE ISCHEMIA; HUMAN; HYPERGLYCEMIA; HYPERLACTATEMIA; HYPONATREMIA; HYPOTENSION; INTENSIVE CARE; LIVER TOXICITY; MORTALITY; NEPHROTOXICITY; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; REVIEW; SEPTIC SHOCK; SIDE EFFECT; SKIN TOXICITY; SYSTEMIC VASCULAR RESISTANCE; TACHYCARDIA; THROMBOCYTOPENIA; TREATMENT OUTCOME; URINE VOLUME;

ADULT; BLOOD PRESSURE; CRITICAL CARE; HUMANS; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; SHOCK, SEPTIC; SKIN DISEASES; VASOCONSTRICTOR AGENTS; VASOPRESSINS;

EID: 3543149438     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.24.11.1050.36144     Document Type: Review

References (46)

1. Angus DC, Linde-Zwirble WT, Lidisker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
2. Rangel-Frausta MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory syndrome (SIRS): a prospective study. JAMA 1995;273:117-23.
3. Centers for Disease Control. Increase in national hospital discharge survey rates for septicemia-United States, 1979-1987. JAMA 1990;263:937-8.
4. Sands KE, Bates DW, Lanken PN, et al. Epidemiology of sepsis syndrome in 8 academic medical centers: academic medical center consortium sepsis project working group. JAMA 1997;278:234-40.
5. Angus DC, Wax RS. Epidemiology of sepsis: an update. Crit Care Med 2001;29:S109-16.
6. Holmes CL, Patel BM, Russell JA, Walley KR. Physiology of vasopressin relevant to management of septic shock. Chest 2001;120:989-1002.
7. Dunser MW, Wenzel V, Mayr AJ, Hasibeder WR. Management of vasodilatory shock: defining the role of arginine vasopressin. Drugs 2003;63:237-56.
8. Sharshar T, Blanchard A, Paillard M, Raphael JC, Gajdos P, Annane D. Circulating vasopressin levels in septic shock. Crit Care Med 2003;31:1752-8.
9. Landry DW, Levin HOUR, Gallant EM, et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997;95:1122-5.
10. Dellinger RP. Cardiovascular management of septic shock. Crit Care Med 2003;31:946-55.
11. Russell JA. Vasopressin in septic shock: clinical equipoise mandates a time for restraint. Crit Care Med 2003;31:2707-9.
12. Schrier RW, Berl T, Anderson RJ. Osmotic and nonosmotic control of vasopressin release. Am J Physiol 1979;236:F321-32.
13. Forrest P. Vasopressin and shock. Anaesth Intensive Care 2001;29:463-72.
14. Vincent J. Hemodynamic support in septic shock. Intensive Care Med 2001;27:S80-92.
15. Anonymous. Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Crit Care Med 1999;27:639-60.
16. Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 2004;32:858-73.
17. Tsuneyoshi I, Yamada H, Kakihana Y, Nakamura M, Nakano Y, Boyle WA III. Hemodynamic and metabolic effects of low-dose vasopressin infusion in vasodilatory shock. Crit Care Med 2001;29:487-93.
18. Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002;96:576-82.
19. Sharshar T, Carlier R, Blanchard A, et al. Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med 2002;30:497-500.
20. Landry DW, Levin HOUR, Gallant EM, et al. Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997;25:1279-82.
21. Malevanov M, Klapholz A, Dinan W, Talavera W. Vasopressin therapy in patients with refractory shock [abstr]. Available from http://www.abstracts-on- line.com/abstracts/ATS/window view.asp?abs=ATS2L_202694. Accessed June 11, 2002.
22. Mann HJ, Beilman GJ, Song JB, Farrell JB, Hasinoff IK, Lohr BC. Outcome of vasopressin treatment in vasodilatory septic shock [abstr]. Crit Care Med 2000;28:A184.
23. Dunser MW, Mayr AJ, Ulmer H, et al. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis. Anesth Analg 2001;93:7-13.
24. Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series. Intensive Care Med 2001;27:1416-21.
25. Obritsch MD, MacLaren R, Jung R, Fish DN. Effects of continuous vasopressin infusion in patients with septic shock [abstr]. Crit Care Med 2003;31:A122.
26. Dabbagh O, Ayoub H, Alshirwai N, Arabi Y, Al Shimemeri A. Use of vasopressin infusion as salvage therapy in septic patients on high dose catecholamines [abstr]. Chest 2003;124:S224.
27. Jackson WL, Ramage AS, Susla GM, Shorr AF. Vasopressin adversely affects cardiac performance in septic shock [abstr]. Available from http://www. abstracts-on-line.com/abstracts/ ATS/windowview.asp?abs=ATS2L_116309. Accessed June 11, 2002.
28. Browning L, Piekos K, Bander J, Guzman J. Conventional versus high-dose titratable vasopressin infusions in the treatment of vasopressor dependent septic shock [abstr]. Crit Care Med 2002;30:A106.
29. Anwar M, Adams RG. Effect of vasopressin on hemodynamic profile in patients with septic shock [abstr]. Available from http://www.abstracts-on-line. com/abstracts/ATS/windowview. asp?abs=ATS2L_201063. Accessed June 11, 2002.
30. Hall LG, Oyen LJ, Taner CB, et al. Vasopressin compared to dopamine and norepinephrine as first-line vasopressor for septic shock [abstr]. Crit Care Med 2001;29:A61.
31. Garcia A, Sandoval J, Aguirre J, Elizalde J, Franco J, Martinez J. Vasopressin infusion improves the hemodynamics in patients with septic shock [abstr]. Crit Care Med 2001;29:A90.
32. Garcia R, Franco J, Aguirre J, Martinez J. Haemodynamic effects of early vasopressin infusion during septic shock [abstr]. Crit Care Med 2002;30:A107.
33. Bracco DC, Revelly JP. Systemic and splanchnic haemodynamic effects of vasopressin administration in vasodilatory shock [abstr]. Intensive Care Med 2001;27:S138.
34. Klinzing S, Simon M, Reinhart K, Bredle DL, Meier-Hellmann A. High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 2003;31:2646-50.
35. Dunser MW, Mayr AJ, Ulmer H, et al. Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled study. Circulation 2003;107:2313-19.
36. Gold JA, Hehn BP, Landry DL. Vasopressin for the treatment of septic shock [abstr]. Am J Resp Crit Care Med 1998;157:A116.
37. Malay MB, Ashton RC, Landry DW, Townsend RT. Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 1999;47:699-705.
38. Dunser MW, Mayr AJ, Tur A, et al. Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistance vasodilatory shock: incidence and risk factors. Crit Care Med 2003;31:1394-8.
39. Altura BM. Dose-response relationships for arginine vasopressin and synthetic analogs on three types of rat blood vessels: possible evidence for regional differences in vasopressin receptor sites within a mammal. J Pharmacol Exp Ther 1975;193:413-23.
40. McVicar AJ. Dose-response effects of pressor doses of arginine vasopressin on renal hemodynamics in the rat. J Physiol 1988;404:535-46,
41. Harrison-Bernard LM, Carmines PK. Juxtamedullary microvascular responses to arginine vasopressin in rat kidney Am J Physiol 1994;267:F249-56.
42. Gonzales JP, Barcelona RA, Arroliga AC. The use of vasopressin in critically ill patients with septic shock [abstr]. Crit Care Med 2002;30:A106.
43. Sun Q, Dimopoulos G, Nguyen DN, et al. Low-dose vasopressin in the treatment of septic shock in sheep. Am J Respir Crit Care Med 2003;168:481-6.
44. Holmes CL, Terins T, Cooper DJ, et al. Vasopressin in septic shock trial (VASST): screening logs identify modifiable patient exclusions in a randomized controlled trial (RCT) [abstr]. Available from http://www.abstracts2view.com/ ats.search.php. Accessed December 15, 2003.
45. Cooper DJ, Russell JA, Walley KR, et al. Vasopressin and septic shock trial (VASST): innovative features and performance [abstr]. Available from http://www.abstracts2 view.com/ats.search.php. Accessed December 15, 2003.
46. Russell JA, Cooper DJ, Walley KR, et al. Vasopressin and septic shock trial (VASST): baseline characteristics and organ dysfunction in vasopressor dependent patients with septic shock [abstr]. Available from http://www.abstracts2view.com/ ats.search.php. Accessed December 15, 2003.